CN116234580A - 次大麻二酚在治疗与同遗传异常有关的罕见癫痫综合征相关的癫痫发作中的用途 - Google Patents

次大麻二酚在治疗与同遗传异常有关的罕见癫痫综合征相关的癫痫发作中的用途 Download PDF

Info

Publication number
CN116234580A
CN116234580A CN202180062304.9A CN202180062304A CN116234580A CN 116234580 A CN116234580 A CN 116234580A CN 202180062304 A CN202180062304 A CN 202180062304A CN 116234580 A CN116234580 A CN 116234580A
Authority
CN
China
Prior art keywords
cbdv
seizures
seizure
preparation
cannabidiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180062304.9A
Other languages
English (en)
Chinese (zh)
Inventor
凯文·詹姆斯·克雷格
约翰·安东尼·劳森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiwei Research Co ltd
Original Assignee
Jiwei Research Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiwei Research Co ltd filed Critical Jiwei Research Co ltd
Publication of CN116234580A publication Critical patent/CN116234580A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202180062304.9A 2020-09-10 2021-09-08 次大麻二酚在治疗与同遗传异常有关的罕见癫痫综合征相关的癫痫发作中的用途 Pending CN116234580A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2014250.1A GB202014250D0 (en) 2020-09-10 2020-09-10 Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2014250.1 2020-09-10
PCT/EP2021/074661 WO2022053486A1 (en) 2020-09-10 2021-09-08 Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

Publications (1)

Publication Number Publication Date
CN116234580A true CN116234580A (zh) 2023-06-06

Family

ID=73149611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062304.9A Pending CN116234580A (zh) 2020-09-10 2021-09-08 次大麻二酚在治疗与同遗传异常有关的罕见癫痫综合征相关的癫痫发作中的用途

Country Status (10)

Country Link
US (1) US20230346809A1 (enExample)
EP (1) EP4210685B1 (enExample)
JP (1) JP7817990B2 (enExample)
KR (1) KR20230066417A (enExample)
CN (1) CN116234580A (enExample)
AU (1) AU2021341452A1 (enExample)
CA (1) CA3191266A1 (enExample)
GB (2) GB202014250D0 (enExample)
MX (1) MX2023002837A (enExample)
WO (1) WO2022053486A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
CA3264785A1 (en) 2022-08-12 2024-02-15 Jazz Pharmaceuticals Research Uk Limited ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487183A (en) * 2011-01-04 2012-07-18 Gw Pharma Ltd Cannabidivarin (CBDV) for use in the treatment of epilepsy
WO2019135075A1 (en) * 2018-01-03 2019-07-11 GW Research Limited Pharmaceutical composition comprising a cannabinoid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI583374B (zh) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
GB2588458A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Cannabidivarin preparations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487183A (en) * 2011-01-04 2012-07-18 Gw Pharma Ltd Cannabidivarin (CBDV) for use in the treatment of epilepsy
WO2019135075A1 (en) * 2018-01-03 2019-07-11 GW Research Limited Pharmaceutical composition comprising a cannabinoid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Public summary of opinion on orphan designation Cannabidivarin for the treatment of Rett syndrome", pages 1 - 4, Retrieved from the Internet <URL:http://www.ema.europa.eu/en/docume ngts/orphan-designation/eu/3/17/1921-public-summary-opinion-orphan-designation-cannabidivarin-treatment-rett-syndrome_en.pdf> *

Also Published As

Publication number Publication date
JP2023540614A (ja) 2023-09-25
GB202112440D0 (en) 2021-10-13
KR20230066417A (ko) 2023-05-15
MX2023002837A (es) 2023-03-17
JP7817990B2 (ja) 2026-02-19
AU2021341452A1 (en) 2023-03-23
CA3191266A1 (en) 2022-03-17
EP4210685B1 (en) 2025-11-26
GB2599492A (en) 2022-04-06
US20230346809A1 (en) 2023-11-02
GB202014250D0 (en) 2020-10-28
WO2022053486A1 (en) 2022-03-17
EP4210685A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
EP4210685B1 (en) Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
EP4181890B1 (en) Use of cannabidiol in the treatment of seizures associated with rett syndrome
WO2022017960A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
EP4259112A1 (en) Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes in patients taking brivaracetam
WO2022017942A1 (en) Use of cannabidiol in the treatment of seizures associated with mutations in the syngap1 gene
AU2020279889A1 (en) Use of cannabidiol in the treatment of epileptic spasms
EP4181893A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017947A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017935A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017911A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
WO2022017946A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017926A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
EP4181900A1 (en) Use of cannabidiol in the treatment of seizures associated with herpes simplex virus
KR20130065646A (ko) 간질의 치료에서 파이토칸나비노이드 칸나비디바린(ｃｂｄｖ)의 용도
WO2022017957A1 (en) Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage
WO2022017944A1 (en) Use of cannabidiol in the treatment of seizures associated with bilateral cerebral dysgenesis
WO2022017929A1 (en) Use of cannabidiol in the treatment of seizures associated lissencephaly
WO2022017930A1 (en) Use of cannabidiol in the treatment of seizures associated with jeavon&#39;s syndrome
WO2022017936A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
EP4181892A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017958A1 (en) Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
WO2022017953A1 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017915A1 (en) Cannabidiol for use in the treatment of seizures associated with brain damage
WO2022017917A1 (en) Cannabidiol for use in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Britain

Address after: Sheffield, Kent, UK

Applicant after: Jazz Pharmaceutical Research UK Ltd.

Address before: Cambridge County, England

Applicant before: Jiwei Research Co.,Ltd.

Country or region before: Britain

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20230606

RJ01 Rejection of invention patent application after publication